KPIs & Operating Metrics(New)
Balance Sheet
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInventory AverageInvested Capital

Takeda Pharmaceutical (TAK) Equity Average (2019 - 2025)

Takeda Pharmaceutical (TAK) has 7 years of Equity Average data on record, last reported at $47.3 billion in Q1 2025.

  • For Q1 2025, Equity Average fell 2.65% year-over-year to $47.3 billion; the TTM value through Mar 2025 reached $47.3 billion, down 2.65%, while the annual FY2025 figure was $48.0 billion, 1.54% down from the prior year.
  • Equity Average reached $47.3 billion in Q1 2025 per TAK's latest filing, down from $48.6 billion in the prior quarter.
  • Across five years, Equity Average topped out at $48.9 billion in Q1 2022 and bottomed at $46.2 billion in Q1 2021.
  • Average Equity Average over 5 years is $47.9 billion, with a median of $48.5 billion recorded in 2023.
  • Peak YoY movement for Equity Average: rose 5.94% in 2022, then fell 2.65% in 2025.
  • A 5-year view of Equity Average shows it stood at $46.2 billion in 2021, then increased by 5.94% to $48.9 billion in 2022, then fell by 0.89% to $48.5 billion in 2023, then increased by 0.18% to $48.6 billion in 2024, then fell by 2.65% to $47.3 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Average were $47.3 billion in Q1 2025, $48.6 billion in Q1 2024, and $48.5 billion in Q1 2023.